BMO Downgrades ResMed (RMD) to Market Perform; $41 PT
More News related to RMD
- ResMed (RMD) Reports Mixed Q1 Earnings
- ResMed Inc. Announces Record Financial Results for the Quarter and Year Ended June 30, 2008
- ResMed to Webcast Fourth Quarter and Fiscal Year End Earnings Conference Call
- Morgan Stanley Downgrades ResMed (RMD) to Underweight
- ResMed (RMD) Could Goto $53 -Cramer
More News related to Downgrades
- Merrill Lynch Downgrades Abercrombie & Fitch (ANF) to Underperform
- Deutsche Bank Lowers Rating On UST Inc (UST) From Buy To Hold
- Lazard Downgrades Navios Maritime (NM) to Hold
- B. Riley Downgrades Captaris (CAPA) to Neutral
- Lazard Downgrades Genco Shipping (GNK) to Hold
BMO Capital downgrades ResMed (NYSE: RMD) from Outperform to Market Perform. The firm has a $41 price target on the stock.
ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of -disordered breathing, including obstructive sleep apnea, and other respiratory disorders that occur during sleep.
Related Categories
DowngradesStocks Mentioned
-0.42Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
